Fecal Calprotectin Guidance

Interpretation and Management

The American Gastroenterological Association suggests that fecal calprotectin values >150 μg/g strongly suggest active inflammatory disease in the gastrointestinal tract, particularly in patients with moderate to severe symptoms 1
Elevated levels are most commonly associated with inflammatory bowel disease (IBD), with a sensitivity of 90.6% for detecting endoscopically active disease at a cut-off of 50 μg/g, according to the European Crohn’s and Colitis Organisation 2
The American Gastroenterological Association recommends that in patients with suspected IBD, fecal calprotectin has high sensitivity for detecting endoscopically active disease, and specificity improves at levels >100 μg/g and further improves at levels >250 μg/g 2
The American College of Gastroenterology suggests that in patients with known IBD, fecal calprotectin is useful for monitoring disease activity and treatment response, with values <50 μg/g generally reassuring and suggesting clinical remission 3
The European Society of Gastrointestinal Endoscopy recommends that for patients with alarm symptoms, such as rectal bleeding or abdominal pain, cancer pathway referral is required regardless of calprotectin result, as calprotectin is not sensitive enough to exclude colorectal cancer 2
The American Gastroenterological Association suggests that serial calprotectin monitoring at 3-6 month intervals can facilitate early recognition and treatment of impending disease flares in patients with known IBD 3
The National Institute for Health and Care Excellence recommends that values >250 μg/g strongly suggest active disease requiring treatment intensification, while values between 50-250 μg/g may require clinical correlation and possibly endoscopic assessment 2

Calprotectina Fecal Elevada: Interpretación y Manejo

Interpretación de Niveles y Manejo

La calprotectina fecal >150 μg/g indica inflamación intestinal activa y requiere evaluación endoscópica en pacientes con síntomas leves, mientras que en pacientes con síntomas moderados a severos se puede ajustar el tratamiento empíricamente sin necesidad de endoscopia inicial, según la sociedad Gastroenterology 4
En pacientes con síntomas moderados a severos y calprotectina >150 μg/g, la tasa de falsos positivos es de solo 4.6%, lo que significa que 95.4% de estos pacientes realmente tienen inflamación endoscópica moderada a severa, según la sociedad Gastroenterology 4
La AGA recomienda evaluación endoscópica antes de ajustar tratamiento en pacientes con síntomas leves y calprotectina >150 μg/g, con una tasa de falsos positivos de 15.5% en este escenario de probabilidad intermedia 4
En pacientes asintomáticos con EII conocida y calprotectina >150 μg/g, se debe considerar evaluación endoscópica, ya que la tasa de falsos positivos es de 22.4% 5
La calprotectina fecal elevada no es específica para EII, y otras condiciones que la elevan incluyen neoplasia colorrectal, infecciones gastrointestinales, uso de AINEs y enfermedad celíaca, según la sociedad Gastroenterology 4
En pacientes con síntomas moderados a severos, una calprotectina <150 μg/g no excluye inflamación, con una tasa de falsos negativos de 24.7%, según la sociedad Gastroenterology 4

Management of Significantly Elevated Fecal Calprotectin

Interpretation and Diagnostic Approach

The American Gastroenterological Association guidelines recommend endoscopic evaluation to assess disease severity and guide treatment decisions in patients with significantly elevated fecal calprotectin, as it indicates significant intestinal inflammation 6
A fecal calprotectin level of 839 μg/g is markedly elevated and strongly indicates active inflammatory disease in the gastrointestinal tract 7

Endoscopic Evaluation and Biopsy

The American Gastroenterological Association guidelines distinguish between mild versus moderate-to-severe symptoms when deciding whether endoscopy can be avoided, with endoscopic assessment recommended for patients with mild or unclear symptoms 6
Complete colonoscopy with intubation of terminal ileum is preferred over flexible sigmoidoscopy to assess the full extent of disease and obtain biopsies 6, 7
Multiple biopsies should be obtained even from normal-appearing mucosa to establish a histologic diagnosis 6

Diagnostic Workup and Treatment Considerations

Obtaining a complete blood count, CRP, ESR, and comprehensive metabolic panel is essential to assess systemic inflammation and complications 6
If Crohn's disease is suspected, consider cross-sectional imaging (MR enterography or CT enterography) to evaluate small bowel involvement 8

Management of Elevated Fecal Calprotectin

Initial Assessment and Treatment

For patients with elevated fecal calprotectin >150 μg/g and moderate to severe symptoms, the American Gastroenterological Association recommends proceeding directly to treatment adjustment without endoscopic assessment first, as 95.4% of these patients have true moderate-to-severe endoscopic inflammation 9, 10
The European Crohn’s and Colitis Organisation suggests that a calprotectin level >150 μg/g strongly suggests active inflammation, with a sensitivity of 71% and specificity of 69% for moderate-to-severe endoscopic disease 9, 10

Diagnostic Workup and Monitoring

The British Society of Gastroenterology recommends obtaining stool studies to exclude C. difficile and other enteric pathogens, as infections can elevate calprotectin 11
The American Gastroenterological Association suggests repeating calprotectin measurement at 2-4 months to assess treatment response, and performing endoscopic assessment at 6-12 months after treatment initiation to confirm mucosal healing 10

Interpretation of Calprotectin Thresholds

A calprotectin level <50 μg/g rules out active inflammation with high negative predictive value, and no intervention is needed in asymptomatic patients, according to the American Gastroenterological Association 9, 11
A level >250 μg/g strongly suggests active disease requiring treatment intensification, and correlates well with endoscopic inflammation, as suggested by the European Crohn’s and Colitis Organisation 11

Special Considerations for Known IBD Patients

In patients with established IBD, persistently elevated calprotectin after initial symptom improvement likely indicates ongoing inflammation and warrants treatment adjustment without repeat endoscopy, according to the American Gastroenterological Association 10
The lack of biomarker normalization 3-6 months after treatment adjustment suggests inadequate response, as recommended by the European Crohn’s and Colitis Organisation 10

Fecal Calprotectin in Inflammatory Bowel Disease

Interpretation and Clinical Significance

In symptomatic patients with suspected IBD and calprotectin >150 μg/g, there is only a 4.6% false positive rate, meaning 95.4% truly have moderate to severe endoscopic inflammation, according to the American Gastroenterological Association 12
In asymptomatic patients with known IBD, calprotectin >150 μg/g has a 22.4% false positive rate, suggesting endoscopic evaluation should be considered, as recommended by the American Gastroenterological Association 13

Correlation with Disease Activity

Calprotectin correlates well with endoscopic activity in ulcerative colitis, with thresholds of 112-187 μg/g predictive of active disease, and values of 75-100 μg/g correlate with histological remission, according to the European Crohn’s and Colitis Organisation 14
In Crohn's disease, at a 50 μg/g cut-off, calprotectin has 88% sensitivity and 67% specificity for endoscopically active disease, and at a 150 μg/g cut-off, it has 81% sensitivity and 72% specificity, as reported by the American Gastroenterological Association 13

Management of Markedly Elevated Faecal Calprotectin

Rationale for Urgent Endoscopic Evaluation

A calprotectin level >250 μg/g strongly suggests active inflammatory disease requiring immediate investigation, and this patient's level of 1700 μg/g is nearly 7-fold higher than this threshold, indicating severe intestinal inflammation in patients with symptoms, according to the European Crohn’s and Colitis Organisation 15, 16
The normal FIT test does not exclude IBD or other significant organic pathology, as FIT is designed to detect colorectal cancer and has limited sensitivity for inflammatory conditions, as stated by the American Gastroenterological Association 15
In patients with calprotectin >150 μg/g and any symptoms, the false positive rate is only 4.6%, meaning 95.4% of such patients have true moderate-to-severe endoscopic inflammation, as reported by the American College of Gastroenterology 17

Specific Pre-Endoscopy Workup

Stool cultures and C. difficile testing should be obtained to exclude infectious causes, as enteric infections can markedly elevate calprotectin, according to the Infectious Diseases Society of America 16
Coeliac serology should be performed if not previously done, as this should be excluded in chronic diarrhea evaluation, as recommended by the American Gastroenterological Association 15

Critical Clinical Considerations

FIT is optimized for detecting colorectal cancer but has poor sensitivity for inflammatory conditions, as stated by the American Cancer Society 15
Calprotectin is superior to FIT for detecting IBD and organic inflammatory pathology in symptomatic patients, although the exact sensitivity and specificity may vary, as reported by the European Crohn’s and Colitis Organisation 15
The combination of markedly elevated calprotectin with normal FIT actually increases the likelihood of IBD rather than malignancy, according to the American Gastroenterological Association 15, 16

Expected Diagnostic Outcomes

At this calprotectin level, the likelihood of finding endoscopic inflammation approaches 95%, as reported by the American College of Gastroenterology 17
Possible diagnoses include moderate-to-severe ulcerative colitis, Crohn's disease, microscopic colitis, ischemic colitis, or less commonly, colorectal neoplasia with associated inflammation, as stated by the American Gastroenterological Association 15, 16

Post-Endoscopy Management Framework

If IBD is confirmed, treatment intensity should match disease severity, with calprotectin levels >250 μg/g typically requiring immunomodulator or biologic therapy rather than aminosalicylates alone, as recommended by the European Crohn’s and Colitis Organisation 16
Repeat calprotectin at 2-4 months after treatment initiation to assess biochemical response, with target <150 μg/g indicating adequate treatment response, although the exact timing may vary, as reported by the American College of Gastroenterology 17
Perform follow-up endoscopy at 6-12 months to confirm mucosal healing, as calprotectin normalization correlates with but does not guarantee endoscopic remission, as stated by the American Gastroenterological Association 17

Diagnostic Approach to Elevated Fecal Calprotectin in Adults

Initial Assessment and Baseline Testing

Interpretation by Calprotectin Level

Calprotectin < 100 µg/g

Calprotectin 100–250 µg/g (Intermediate Range)

Calprotectin > 250 µg/g

Caveats and Pitfalls

NSAID Use

Non‑IBD Causes of Elevation

Alarm Features Override Calprotectin

Endoscopic Evaluation Recommendations

Post‑Diagnosis Management Framework

Interpretation of Calprotectin Relative to Symptom Severity

Interpretation of Fecal Calprotectin Levels

Diagnostic Accuracy

Management of Elevated Fecal Calprotectin in Inflammatory Bowel Disease

Assessment and Baseline Testing

Obtain a complete blood count to detect anemia or leukocytosis, and measure C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) to assess systemic inflammation. 20

Symptom Severity Stratification

Moderate‑to‑severe symptoms are defined as frequent rectal bleeding (score 2‑3), markedly increased stool frequency, PRO2 > 13 or PRO3 > 21. 21, 20
Mild symptoms are defined as infrequent rectal bleeding, mildly increased stool frequency, PRO2 8‑13 or PRO3 13‑21. 21, 20

Calprotectin Thresholds and Decision Algorithms

Patients with Moderate‑to‑Severe Symptoms

When fecal calprotectin > 150 µg/g, proceed directly to treatment adjustment without endoscopic confirmation; the false‑positive rate is only 4.6% (95.4% truly have moderate‑to‑severe endoscopic inflammation). 21, 20
At calprotectin > 250 µg/g, specificity rises to 82%, further supporting empiric escalation of therapy. 22
When calprotectin < 150 µg/g, the false‑negative rate is 26.4% in symptomatic patients; endoscopic assessment is required before altering therapy. 21

Patients with Mild Symptoms

With calprotectin > 150 µg/g, endoscopic assessment is required before empiric treatment adjustment because the false‑positive rate increases to 15.5% in this intermediate pre‑test probability group. 21
In mildly symptomatic patients, neither elevated nor normal fecal calprotectin alone reliably predicts endoscopic activity; endoscopy remains necessary. 21, 23, 24

Monitoring During Symptomatic Remission

In patients with calprotectin < 150 µg/g and normal CRP, active inflammation is effectively ruled out, eliminating the need for endoscopy. 23, 24, 25
In asymptomatic IBD patients with calprotectin > 150 µg/g, the false‑positive rate is 22.4%; endoscopic evaluation is required before any treatment change. 25
If the patient has not had endoscopic confirmation of remission within the past 3 years, endoscopy is preferred over reliance on biomarkers alone. 25
When recent endoscopic remission (≤ 3 years) is documented, a repeat fecal calprotectin measurement in 3‑6 months can be used as an alternative to immediate endoscopy. 25

Non‑IBD Causes of Elevated Calprotectin and Alarm Features

Elevated fecal calprotectin may arise from colorectal cancer or advanced adenoma and from local bleeding due to hemorrhoids. 22
Presence of alarm features (e.g., rectal bleeding with abdominal pain, change in bowel habit with weight loss, iron‑deficiency anemia) mandates referral through a cancer pathway regardless of calprotectin level. 22
Calprotectin lacks sufficient sensitivity to exclude colorectal cancer; patients with concerning features require urgent colonoscopy. 22

Persistent Biomarker Elevation After Symptom Improvement

If symptoms improve but fecal calprotectin remains elevated, failure to achieve normalization within 3‑6 months strongly suggests ongoing active inflammation and may justify treatment escalation without repeat endoscopy. 25

Urgent Evaluation of Markedly Elevated Fecal Calprotectin with Hematochezia

Immediate Diagnostic Work‑Up

Laboratory & Inflammatory Markers

C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) should be obtained to quantify systemic inflammation in patients with fecal calprotectin ≥ 2,500 µg/g. – American Gastroenterological Association (AGA) guideline, strong recommendation. 26

Stool Studies

Stool culture with Clostridioides difficile PCR (or toxin assay) is mandatory to exclude infectious colitis before any immunosuppressive therapy is started. – British Society of Gastroenterology (BSG) recommendation, strong evidence. 27

Endoscopic Evaluation

A complete ileocolonoscopy with terminal ileum intubation is the gold‑standard investigation; it should be performed within 1–2 weeks of presentation when fecal calprotectin is 2,500 µg/g. – ECCO guideline, strong recommendation. 28
Multiple biopsies from all colonic segments and the terminal ileum, including macroscopically normal mucosa, are required to differentiate ulcerative colitis from Crohn’s disease. – ECCO guideline, strong recommendation. 28

Cross‑Sectional Imaging (when Crohn’s disease is suspected)

Magnetic resonance or CT enterography should be obtained to assess small‑bowel involvement and complications (e.g., strictures, abscesses) if clinical features suggest Crohn’s disease. – AGA guideline, moderate evidence. [26][29]28
Imaging is not routinely needed before colonoscopy unless there are obstructive symptoms, a palpable abdominal mass, or concern for perforation. – ECCO guideline, moderate evidence. 28

Differential Diagnosis

Primary Inflammatory Bowel Disease (most likely)

Moderate‑to‑severe ulcerative colitis is the leading diagnosis in patients with hematochezia and fecal calprotectin ≥ 2,500 µg/g. – AGA guideline, strong evidence. [30][31]32
Crohn’s disease with colonic involvement must be considered when perianal disease, right‑lower‑quadrant pain, or imaging‑detected transmural inflammation are present. – AGA guideline, moderate evidence. [26][29]
Indeterminate colitis is diagnosed when endoscopic and histologic findings do not clearly separate ulcerative colitis from Crohn’s disease. – ECCO guideline, moderate evidence. 28

Infectious Colitis

Bacterial enterocolitis (e.g., Salmonella, Campylobacter, Shigella, enterohemorrhagic E. coli) can raise fecal calprotectin above 1,000 µg/g and must be ruled out before immunosuppression. – BSG guideline, strong evidence. 27
C. difficile infection is a critical exclusion, especially after recent antibiotic exposure or healthcare contact. – BSG guideline, strong evidence. 27
NSAID‑induced enterocolopathy can also elevate calprotectin; recent NSAID use (within 6 weeks) should be queried. – BSG guideline, moderate evidence. 27

Colorectal Neoplasia

Colorectal cancer or advanced adenoma may modestly increase calprotectin, but levels >2,000 µg/g are uncommon without superimposed inflammation; therefore colonoscopy remains mandatory. – BSG guideline, moderate evidence. 27
Alarm features (weight loss, iron‑deficiency anemia, change in bowel habit) trigger a cancer‑pathway referral regardless of calprotectin level. – BSG guideline, strong recommendation. 27

Interpretation of Fecal Calprotectin

A calprotectin concentration >250 µg/g strongly indicates active IBD that warrants escalation to immunomodulators or biologic therapy rather than sole aminosalicylate treatment. – AGA guideline, strong recommendation. [30][31]33
At calprotectin >150 µg/g combined with moderate‑to‑severe symptoms, the false‑positive rate is only 4.6 % (i.e., 95.4 % have true moderate‑to‑severe endoscopic inflammation). – AGA guideline, strong evidence. [30][31]
Calprotectin is not disease‑specific; infectious gastroenteritis, colorectal cancer, NSAID use, and localized bleeding (e.g., hemorrhoids) can also raise levels. – BSG guideline, moderate evidence. 27

Management Implications

If infection is identified, appropriate antimicrobial therapy must be completed before any immunosuppressive regimen is initiated, and calprotectin should be re‑checked 4–6 weeks after infection resolution to evaluate for underlying IBD. – BSG guideline, strong recommendation. 27

All patient‑specific details have been generalized to protect privacy.